Bimagrumab
DrugBimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
Other names: BYM338
NCT Number: NCT02333331
The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.
Looking for future studies?
Notify Me70 year and older
All sexes
Interventional
Phase 2
Novartis Investigative Site, Adelaide, South Australia, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
Other names: BYM338
Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
Other names: 5% dextrose
Time frame: Baseline, week 25
Change from Baseline in total Short Physical Performance Battery (SPPB) Score to week 25; SPPB is a series of six activities involving three domains of physical function - balance, usual walking speed and rising from a chair , is commonly used globally to assess and quantify (score 0-12) lower extremity function and has been shown to predict future adverse health events. A decline of one or more points in the SPPB total score is predictive of a decrease in lower extremity function and future adverse clinical outcomes in older adults, including falls, hospitalizations, institutionalization, incident disability and death
Time frame: Baseline, week 25
Change from Baseline at Week 25 in the 6 minute walk test (6MWT) distance to measure improvement in physical function
Time frame: baseline, week 25
Change from Baseline to Week 25 in usual Gait speed (GS) over 4 meters Gait speed in this study was assessed as part of the SPPB, over a 4 meter distance of a 6 meter course. This test assessed a person's usual walking speed, which was defined as the speed a person normally walks from one place to another without urgency (e.g., walking down a hallway).
Time frame: baseline, week 25
Change from Baseline to Week 25 on appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) Appendicular skeletal muscle index (ASMI) is a core requirement for determining the presence of sarcopenia and is calculated as the sum of the appendicular lean mass (kg) of the two upper and two lower limbs quantified by DXA, divided by height (m^2). Therefore, an increase in ASMI indicates an increase in the quantity of an individual's lean mass.
Time frame: baseline, week 25
Change from Baseline to Week 25 on Total lean body mass and appendicular skeletal muscle index (ASMI) measured by Dual Energy X-ray Absorptiometry (DXA) total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = [(LBM at Visit - LBM at Baseline) / LBM at Baseline] * 100.
Novartis Pharmaceuticals
Industry
A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06910254
Atrophy, Brain Diseases
Seoul, South Korea
View Trial DetailsNCT06403137
Atrophy, Kwashiorkor
Maastricht, Limburg, Netherlands
View Trial DetailsNCT06205784
Atrophy, Disuse Atrophy
Copenhagen, Capital Region, Denmark
View Trial DetailsNCT02912130
Atrophy, Behavior
Liverpool, Merseyside, United Kingdom
View Trial Details